512.81
-2.65 (-0.51%)
| 前收盘价格 | 515.46 |
| 成交量 | 116,162 |
| 预期市盈率 (P/E Forward) | 18.80 |
| 价格/销量 (P/S) | 7.68 |
| 股市价格/股市净资产 (P/B) | 3.46 |
| 52周波幅 |
| 营业毛利率 | 40.44% |
| 营业利益率 (TTM) | 48.19% |
| 稀释每股收益 (EPS TTM) | 25.11 |
| 季度收入增长率 (YOY) | 17.20% |
| 季度盈利增长率 (YOY) | 5.10% |
| 总债务/股东权益 (D/E MRQ) | 2.94% |
| 流动比率 (MRQ) | 5.46 |
| 营业现金流 (OCF TTM) | 1.41 B |
| 杠杆自由现金流 (LFCF TTM) | 825.79 M |
| 资产报酬率 (ROA TTM) | 12.93% |
| 股东权益报酬率 (ROE TTM) | 19.94% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | United Therapeutics Corporation | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -3.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -5.0 |
| 平均 | -1.80 |
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Mid Core |
| 内部持股比例 | 1.75% |
| 机构持股比例 | 100.69% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MAHON PAUL A | - | 521.00 | -8,300 | -4,324,300 |
| ROTHBLATT MARTINE A | - | 518.52 | -66,500 | -34,481,390 |
| 累积净数量 | -74,800 | |||
| 累积净值 ($) | -38,805,690 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 518.83 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | 职员 | 26 Aug 2026 | 自动卖出 (-) | 9,500 | 516.68 | 4,908,460 |
| ROTHBLATT MARTINE A | 职员 | 26 Aug 2026 | 执行期权 | 9,500 | - | - |
| ROTHBLATT MARTINE A | 职员 | 25 Aug 2026 | 自动卖出 (-) | 9,500 | 518.53 | 4,926,035 |
| ROTHBLATT MARTINE A | 职员 | 25 Aug 2026 | 执行期权 | 9,500 | - | - |
| ROTHBLATT MARTINE A | 职员 | 24 Aug 2026 | 自动卖出 (-) | 9,500 | 512.88 | 4,872,360 |
| ROTHBLATT MARTINE A | 职员 | 24 Aug 2026 | 执行期权 | 9,500 | - | - |
| ROTHBLATT MARTINE A | 职员 | 21 Aug 2026 | 自动卖出 (-) | 9,500 | 513.12 | 4,874,640 |
| ROTHBLATT MARTINE A | 职员 | 21 Aug 2026 | 执行期权 | 9,500 | - | - |
| MAHON PAUL A | 职员 | 20 Aug 2026 | 自动卖出 (-) | 8,300 | 521.00 | 4,324,300 |
| MAHON PAUL A | 职员 | 20 Aug 2026 | 执行期权 | 8,300 | - | - |
| ROTHBLATT MARTINE A | 职员 | 20 Aug 2026 | 自动卖出 (-) | 9,500 | 521.00 | 4,949,500 |
| ROTHBLATT MARTINE A | 职员 | 20 Aug 2026 | 执行期权 | 9,500 | - | - |
| ROTHBLATT MARTINE A | 职员 | 19 Aug 2026 | 自动卖出 (-) | 9,500 | 529.14 | 5,026,830 |
| ROTHBLATT MARTINE A | 职员 | 19 Aug 2026 | 执行期权 | 9,500 | - | - |
| ROTHBLATT MARTINE A | 职员 | 18 Aug 2026 | 自动卖出 (-) | 9,500 | 518.27 | 4,923,565 |
| ROTHBLATT MARTINE A | 职员 | 18 Aug 2026 | 执行期权 | 9,500 | - | - |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合